We expect better of the VA medical care system. Our veterans deserve better.
On the public record
All Quotes
Every politician on the site, every statement on file. Search, filter, and read the public record.
12,000+·quotes on file
Would you agree that these veterans, frustrated by access to critical care, would be at elevated risk for suicide?
I am very concerned about how the VA has interpreted and differentiated between institutional and uninstitutional extended care.
I would have liked to have addressed the initiatives they are talking about today.
One death from substance use disorder is one too many.
Prohibits deceptive, unfair pricing schemes, including spread pricing and arbitrary clawbacks of payments made to pharmacies.
The Pharmacy Benefit Manager (PBM) Transparency Act (S. 127) requires transparency reporting by PBMs to shine sunlight on prices and fees associated with prescription drugs.
In the Grassley-Wyden 2-year investigation into insulin price-gouging, we found that that PBM scheme encourages drug makers to spike the drug list price.
This bill puts sunshine on PBMs and saves taxpayers $740 million.
The current drug price system is so opaque that it is easy to see why there are many questions about PBM motives and practices.
Prohibits deceptive, unfair pricing schemes, including spread pricing and arbitrary clawbacks of payments made to pharmacies.
The Pharmacy Benefit Manager (PBM) Transparency Act (S. 127) requires transparency reporting by PBMs to shine sunlight on prices and fees associated with prescription drugs.
I believe the key way that we can solve high prescription drug prices is to have more transparency.
In the Grassley-Wyden 2-year investigation into insulin price-gouging, we found that that PBM scheme encourages drug makers to spike the drug list price.
This bill puts sunshine on PBMs and saves taxpayers $740 million.
The current drug price system is so opaque that it is easy to see why there are many questions about PBM motives and practices.
The Prescription Pricing for the People bill requires the FTC to study pharmaceutical intermediaries, including vertical integration.
Something ought to get done this Congress, considering the fact that there is already a bill out of Judiciary, a bill out of Commerce.